are take-privates; 6 of 13 investments partially or fully realized Skis Transaction Investment Fund I Deal Type Date Legacy (Bond) Business Next-Gen (Call Option) Business Status Web.com. III & IV I Taketrivate Oct. 2018 • I )tnna In r' strat ion and related value. added set ties • Niche s

We are raising our Price Target on F5, from $120 to $130; reflecting our improved conviction on F5's next-phase growth opportunities in Telco and in Next-Gen Security - following our MWC and RSA conference meetings. Our key insight on F5 is our higher conviction on the company's next-phase growth opportu

to diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, D=NSR for NIPD of trisomy), and identify diseases using DNA microarrays a=d targeted Next-Gen sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr.

to diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, =ANSR for NIPD of trisomy), and identify diseases using DNA microarray= and targeted Next-Gen sequencing. Earlier this year, I re=eived the IFCC Award for Significant Contributions in Molecular Diagn=stics. I have been collaborating with Dr.

o diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, C0=NSR for NIPD of trisomy), and identify diseases using DNA microarrays a=d targeted Next-Gen sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr.